Macromolecular drugs are very promising as improved therapeutics for numerous serious disorders such as cancer and cardiovascular disease. Lab equipment is available for macromolecular X-ray diffraction crystallography, but suffers from lengthy processing times compared to synchrotron sources. Expanded capabilities such as a full understanding of the 3-D structure, and possibly the function of a macromolecule, is needed to develop efficient, safe and specific delivery mechanisms. 3-D holographic and coherent diffraction imaging are keys to this, but this requires access to a limited number of very expensive facilities worldwide for a step towards this capability.
We will specialize in laser development, for macromolecular drug development.
For example, our laser will offer advances in the area of X-ray holography for the time resolved capability of measuring the 3-D change of a molecule subject to some sort of stimulus – i.e. laser output. At a two-orders of magnitude cost reduction on synchrotrons, with similar energies, and speed of processing due to a 3 to 5 orders of magnitude increase in photons per shot over current lab equipment, advanced macromolecular R&D will be affordable to research organizations, universities, and across the BioPharma and pharmaceutical industries.
Contact us to find out more.